Myriad Updates Investors on Companion Dx Deals, EU Expansion, and Capturing Asymptomatic Market

During Myriad's investor day last week, officials disclosed that the firm is working with pharmaceutical companies to develop companion diagnostics for PARP inhibitors and PTEN inhibitors.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.